Severe pulmonary toxoplasmosis after allo-SCT in two patients: from Toxoplasma genotyping to clinical management.
Delhaes
L
L
Mraz
J-C
JC
Fréalle
E
E
Durand-Joly
I
I
Magro
L
L
Ajzenberg
D
D
Dardé
M-L
ML
Dei-Cas
E
E
Yakoub-Agha
I
I
D000293:Adolescent; D000328:Adult; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects; D005260:Female; D005838:Genotype; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D016867:Immunocompromised Host; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000628:therapy; D008174:Lung Diseases, Parasitic / Q000188:drug therapy / Q000209:etiology* / Q000469:parasitology; D008297:Male; D009190:Myelodysplastic Syndromes / Q000628:therapy; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology / Q000469:parasitology; D012307:Risk Factors; D014122:Toxoplasma / Q000145:classification / Q000235:genetics / Q000302:isolation & purification; D014123:Toxoplasmosis / Q000188:drug therapy / Q000209:etiology* / Q000469:parasitology; D014184:Transplantation, Homologous
D000981:Antiprotozoal Agents